INAB logo

IN8BIO INC

INABNASDAQ
πŸ† #4826 by market capEarnings Nov 4US Equity
$1.02β–² $0.06 (+6.25%)
Market closed Β· at close
πŸ””
Track INAB
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 6.3%
7dβ–Ό 6.4%
14dβ–Ό 10.5%
30dβ–Ό 20.6%
ytdβ–Ό 56.4%
1yβ–Ό 50.5%
🏦Market Cap
$10M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.98 – $1.05
52-Week Range
$0.87 – $2.73
Volume (shares)
13,120
Avg Volume (shares)
β€”
Shares Outstanding
9.9M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-0.5
P/S Ratio
0.0x
EPS (TTM)
$-0.96
Dividend Yield
0.00%
Dilution (1yr)
+304.2%
INAB logo

IN8BIO INC

INAB
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$20Mβ–Ό βˆ’34.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$13Mβ–Ό βˆ’47.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
9.8Mβ–² +304.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$24Mβ–² +$18M YoY
StockOtter Β· stockotter.space

About IN8BIO INC

IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
9 analysts
Strong Buy2
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

GlobeNewsWireΒ·22d ago

IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the β€œCompany”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (Ξ³Ξ΄) T cell therapies and T cell engagers for cancer a

Defense WorldΒ·Sep 28

IN8bio Highlights Glioblastoma Survival Data, Eyes Autoimmune T-Cell Engager Milestone

IN8bio (NASDAQ: INAB) outlined updates across its gamma-delta T-cell programs in autoimmune disease and oncology, including preclinical plans for its T-cell engager platform and clinical data in glioblastoma. President,

GlobeNewsWireΒ·Sep 22

IN8bio to Present at Sidoti Small-Cap Virtual Conference

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (Ξ³Ξ΄) T cell therapies and T cell engagers for cancer and autoimmune d

GlobeNewsWireΒ·Sep 10

IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (Ξ³Ξ΄) T cell therapies and T cell engagers for cancer and autoimmune d

GlobeNewsWireΒ·Sep 9

IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

Renowned Ξ³Ξ΄ T cell and T cell engager (TCE) expert brings two decades of drug discovery and development experience to IN8bio Appointment strengthens IN8bio's leadership and domain expertise as they advance their novel Ξ³Ξ΄